STOCK TITAN

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

Rhea-AI Summary
NRx Pharmaceuticals has signed a development contract to manufacture intravenous Ketamine suitable for treating depression and suicidality. The company plans to file a New Drug Application for Ketamine in 2024 based on existing clinical data and newly-developed manufacturing protocols. The supply of Ketamine is currently limited and not labeled for depression treatment. NRx Pharmaceuticals and its manufacturing partner will release more information in an upcoming 8K filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals receives FDA approval to proceed with a pharmacokinetic study for NRX-101 in the treatment of Chronic Pain. The requirements are consistent with those for Bipolar Depression, potentially allowing for registrational studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals accelerates plans to develop commercial form of intravenous ketamine for treating acute depression and suicidality
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
none
Rhea-AI Summary
NRx Pharmaceuticals to present corporate overview at 8th Annual Dawson James Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
Rhea-AI Summary
NRx Pharmaceuticals receives FDA clearance to proceed with human trials for NRX-101 to treat Chronic Pain. Plans to seek Fast Track and Breakthrough Therapy Designations. Company has sufficient quantities of investigational drug to launch registrational studies in 2024. Chronic pain industry estimated to be $72 billion today, with potential to grow to $120 billion by 2033. D-cycloserine (DCS) has shown potential to reduce opioid craving and has no potential for addiction. Statistical results of confirmatory trial funded by US Department of Defense expected in coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.38%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals announces data sharing agreement for Ketamine study, potential NDA filing in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
Rhea-AI Summary
NRx Pharmaceuticals to present company overview at Sidoti Virtual Small Cap Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.82%
Tags
conferences
-
Rhea-AI Summary
NRx Pharmaceuticals signs data sharing agreement for ketamine trial, plans to present data to FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
none
-
Rhea-AI Summary
NRx Pharmaceuticals appoints Richard Narido as Interim Chief Financial Officer, accepting the resignation of Seth Van Voorhees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
none
Rhea-AI Summary
NRx Pharmaceuticals to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach